Part I Overview Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients, are left untreated. Conventional gene therapy is an attractive potential treatment approach for only a limited number of monogenic diseases due to the challenges caused by the complex biology of neurological diseases and by inherent variable transgene uptake and expression. We are a clinical-stage biotechnology company committed to overcoming t...
Q2 FY2026 — expected 2026-08-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001404644-26-000019 | EDGAR | 103K words |
| 2025-03-24 | 2024-12-31 | 0001404644-25-000012 | EDGAR | — |
| 2024-03-18 | 2023-12-31 | 0001404644-24-000020 | EDGAR | — |
| 2023-03-20 | 2022-12-31 | 0001628280-23-008602 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001628280-22-004491 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001628280-21-005630 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001193125-20-071545 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001193125-19-066506 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001193125-18-079210 | EDGAR | — |
| 2017-03-09 | 2016-12-31 | 0001193125-17-076939 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001404644-26-000059 | EDGAR | — |
| 2025-11-13 | 2025-09-30 | 0001404644-25-000101 | EDGAR | 64K words |
| 2025-08-11 | 2025-06-30 | 0001404644-25-000081 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001404644-25-000041 | EDGAR | — |
| 2024-11-18 | 2024-09-30 | 0001404644-24-000104 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001404644-24-000086 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001404644-24-000057 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001628280-23-038797 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001628280-23-028856 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016425 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001628280-22-029833 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001628280-22-021923 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-11 | 0001404644-26-000056 | EDGAR | — |
| 2026-03-24 | 0001404644-26-000012 | EDGAR | 4K words |
| 2026-02-26 | 0001404644-26-000006 | EDGAR | — |
| 2026-01-12 | 0001404644-26-000003 | EDGAR | — |
| 2025-11-13 | 0001404644-25-000103 | EDGAR | — |
| 2025-11-12 | 0001404644-25-000098 | EDGAR | — |
| 2025-11-06 | 0001404644-25-000091 | EDGAR | — |
| 2025-10-09 | 0001404644-25-000088 | EDGAR | — |
| 2025-08-11 | 0001404644-25-000082 | EDGAR | — |
| 2025-06-30 | 0001404644-25-000070 | EDGAR | — |
229 total filings indexed. 197 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001404644 |
| Ticker | NGNE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.neurogene.com |
| Listed | 2023-12-19 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NGNE (~200 tokens, structured JSON with cryptographic provenance)